{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:55:07Z","timestamp":1770976507680,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018609","name":"High-level Hospital Construction Project of Guangdong Provincial People's Hospital","doi-asserted-by":"publisher","award":["DFJH201908"],"award-info":[{"award-number":["DFJH201908"]}],"id":[{"id":"10.13039\/501100018609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81,470,974"],"award-info":[{"award-number":["81,470,974"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82,170,731"],"award-info":[{"award-number":["82,170,731"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.intimp.2024.113379","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:00:02Z","timestamp":1729098002000},"page":"113379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"P2","title":["The outcomes of primary membranous nephropathy treated with cyclophosphamide are superior to calcineurin inhibitors in patients with renal vascular lesions: A multi-center retrospective cohort study"],"prefix":"10.1016","volume":"143","author":[{"given":"Yifan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianteng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaogui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaosheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yau","family":"Hok Him","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zujiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuling","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruizhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.intimp.2024.113379_b0005","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin Nephrol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113379_b0010","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary Membranous Nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113379_b0015","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"Journal of the American Society of Nephrology: JASN."},{"issue":"1","key":"10.1016\/j.intimp.2024.113379_b0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.113379_b0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0272-6386(04)00809-1","article-title":"Immunosuppressive treatment for idiopathic membranous nephropathy: a systematic review","volume":"44","author":"Perna","year":"2004","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.intimp.2024.113379_b0030","unstructured":"Problems K. National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC) Kidney and Urologic Diseases Statistics for the United States. 2010."},{"key":"10.1016\/j.intimp.2024.113379_b0035","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2020111583","article-title":"Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study","author":"Go","year":"2021","journal-title":"Journal of The American Society of Nephrology."},{"issue":"2","key":"10.1016\/j.intimp.2024.113379_b0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1016\/j.intimp.2024.113379_b0045","doi-asserted-by":"crossref","unstructured":"Rovin, B.H., Adler, S.G., Barratt, J., Bridoux, F., Burdge, K.A., Chan, T.M., Cook, H.T., Fervenza, F.C., Gibson, K.L., Glassock, R.J. and Jayne, D.R., KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int, 2021;100(4), S1-S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021.","DOI":"10.1016\/j.kint.2021.05.021"},{"issue":"5","key":"10.1016\/j.intimp.2024.113379_b0050","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/his.13955","article-title":"Histological grading in primary membranous nephropathy is essential for clinical management and predicts outcome of patients","volume":"75","author":"Stangou","year":"2019","journal-title":"Histopathology."},{"issue":"3","key":"10.1016\/j.intimp.2024.113379_b0055","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40620-014-0057-0","article-title":"Pathological predictors of renal outcomes in nephrotic idiopathic membranous nephropathy with decreased renal function","volume":"27","author":"Chen","year":"2014","journal-title":"J Nephrol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113379_b0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5301\/jn.5000174","article-title":"Pathogenesis of calcineurin inhibitor-induced hypertension","volume":"25","author":"Hoorn","year":"2012","journal-title":"Journal of Nephrology."},{"issue":"9868","key":"10.1016\/j.intimp.2024.113379_b0065","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S0140-6736(12)61566-9","article-title":"Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial","volume":"381","author":"Howman","year":"2013","journal-title":"The Lancet."},{"issue":"1","key":"10.1016\/j.intimp.2024.113379_b0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jfma.2015.07.021","article-title":"Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy","volume":"115","author":"Peng","year":"2016","journal-title":"Journal of the Formosan Medical Association."},{"issue":"5","key":"10.1016\/j.intimp.2024.113379_b0075","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3109\/08860221003728754","article-title":"Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy","volume":"32","author":"Kosmadakis","year":"2010","journal-title":"Renal Failure."},{"key":"10.1016\/j.intimp.2024.113379_b0080","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Ju\u00e1rez G, Rojas-Rivera J, Logt AV, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986-998. https:\/\/doi.org\/10.1016\/j.kint.2020.10.014.","DOI":"10.1016\/j.kint.2020.10.014"},{"issue":"4","key":"10.1016\/j.intimp.2024.113379_b0085","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.intimp.2024.113379_b0090","doi-asserted-by":"crossref","unstructured":"Cattran, D.C., Feehally, J., Cook, H.T., Liu, Z.H., Fervenza, F.C., Mezzano, S.A., Floege, J., Nachman, P.H., Gipson, D.S., Praga, M. and Glassock, R.J., Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group Chapter 7: Idiopathic membranous nephropathy. Kidney Int Suppl. 2012;2(2):186-197. https:\/\/doi.org\/10.1038\/kisup.2012.20.","DOI":"10.1038\/kisup.2012.20"},{"issue":"1","key":"10.1016\/j.intimp.2024.113379_b0105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/0886022X.2020.1713806","article-title":"Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy","volume":"42","author":"Guo","year":"2020","journal-title":"Ren Fail."},{"key":"10.1016\/j.intimp.2024.113379_b0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lfs.2016.04.012","article-title":"Treatment of membranous nephropathy with mizoribine: A control trial","volume":"154","author":"Wang","year":"2016","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2024.113379_b0115","doi-asserted-by":"crossref","unstructured":"Zheng Q, Yang H, Liu W, et al. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis. BMJ Open. 2019;9(9):e030919. https:\/\/doi.org\/10.1136\/bmjopen-2019-030919.","DOI":"10.1136\/bmjopen-2019-030919"},{"key":"10.1016\/j.intimp.2024.113379_b0120","doi-asserted-by":"crossref","unstructured":"Shang SL, Cai GY, Duan SW, Li P, Li QG, Chen XM. Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy. BMC Nephrol. 2018;19(1):182. https:\/\/doi.org\/10.1186\/s12882-018-0967-5.","DOI":"10.1186\/s12882-018-0967-5"},{"issue":"9","key":"10.1016\/j.intimp.2024.113379_b0125","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.113379_b0130","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/0272-6386(95)90568-5","article-title":"A review of therapeutic studies of idiopathic membranous glomerulopathy","volume":"25","author":"Hogan","year":"1995","journal-title":"Am J Kidney Dis."},{"issue":"12","key":"10.1016\/j.intimp.2024.113379_b0135","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1681\/ASN.2015010091","article-title":"Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy","volume":"26","author":"Thompson","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.intimp.2024.113379_b0140","doi-asserted-by":"crossref","unstructured":"Praga M, Barrio V, Juarez GF, Luno J, Grupo Espanol de Estudio de la Nefropatia M. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924-30. https:\/\/doi.org\/10.1038\/sj.ki.5002215.","DOI":"10.1038\/sj.ki.5002215"},{"issue":"4","key":"10.1016\/j.intimp.2024.113379_b0145","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.intimp.2024.113379_b0150","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis."},{"issue":"24","key":"10.1016\/j.intimp.2024.113379_b0155","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA."},{"key":"10.1016\/j.intimp.2024.113379_b0160","doi-asserted-by":"crossref","unstructured":"Zhang Y, Jiang Q, Xie J, et al. Modified arteriosclerosis score predicts the outcomes of diabetic kidney disease. BMC Nephrol. 2021;22(1):281. https:\/\/doi.org\/10.1186\/s12882-021-02492-x.","DOI":"10.1186\/s12882-021-02492-x"},{"key":"10.1016\/j.intimp.2024.113379_b0165","unstructured":"Bonsib SM. Renal Anatomy and Histology. In: Jennette JC, D'Agati VD, Olson JL, Silva FG, eds. Heptinstall's Pathology of the Kidney. 7th ed. Wolters Kluwer Health; 2014:11-157:chap 1. vol. 1."},{"issue":"14","key":"10.1016\/j.intimp.2024.113379_b0170","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJM197609302951401","article-title":"Treatment of idiopathic membranous nephropathy","volume":"295","author":"Ehrenreich","year":"1976","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.113379_b0175","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic classification of diabetic nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.intimp.2024.113379_b0180","doi-asserted-by":"crossref","unstructured":"Working Group of the International Ig ANN, the Renal Pathology S, Cattran DC, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534-45. https:\/\/doi.org\/10.1038\/ki.2009.243.","DOI":"10.1038\/ki.2009.243"},{"issue":"10","key":"10.1016\/j.intimp.2024.113379_b0185","first-page":"1191","article-title":"Intention-to-treat analysis in clinical trials: principles and practical importance","volume":"21","author":"Soares","year":"2002","journal-title":"Rev Port Cardiol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113379_b0190","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: Issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med."},{"issue":"25","key":"10.1016\/j.intimp.2024.113379_b0195","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.113379_b0200","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.intimp.2024.113379_b0205","doi-asserted-by":"crossref","unstructured":"Nankivell BJ, P\u02bcNg CH, O\u02bcConnell PJ, Chapman JR. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. Transplantation. 2016;100(8):1723-31. https:\/\/doi.org\/10.1097\/TP.0000000000001243.","DOI":"10.1097\/TP.0000000000001243"},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2024.113379_b0210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/nep.12461","article-title":"Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity","volume":"20","author":"Yagisawa","year":"2015","journal-title":"Nephrology (Carlton)."},{"issue":"12","key":"10.1016\/j.intimp.2024.113379_b0215","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1097\/00007890-199812270-00029","article-title":"Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group","volume":"66","author":"Solez","year":"1998","journal-title":"Transplantation."},{"key":"10.1016\/j.intimp.2024.113379_b0220","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.fct.2018.06.054","article-title":"Mechanism of cyclosporine A nephrotoxicity: Oxidative stress, autophagy, and signalings","volume":"118","author":"Wu","year":"2018","journal-title":"Food Chem Toxicol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113379_b0230","doi-asserted-by":"crossref","first-page":"564","DOI":"10.5301\/jn.5000199","article-title":"Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids","volume":"26","author":"He","year":"2013","journal-title":"J Nephrol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113379_b0235","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MAJ.0b013e3181ca3a7d","article-title":"Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial","volume":"339","author":"Chen","year":"2010","journal-title":"Am J Med Sci."},{"key":"10.1016\/j.intimp.2024.113379_b0240","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000348475","article-title":"Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial","volume":"181","author":"Xu","year":"2013","journal-title":"Contrib Nephrol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113379_b0245","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ekir.2017.02.004","article-title":"Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide","volume":"2","author":"Ramachandran","year":"2017","journal-title":"Kidney Int Rep."},{"issue":"3","key":"10.1016\/j.intimp.2024.113379_b0250","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/aje\/kwj047","article-title":"Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect","volume":"163","author":"Kurth","year":"2006","journal-title":"Am J Epidemiol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924019015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924019015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T02:31:30Z","timestamp":1736303490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924019015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":47,"alternative-id":["S1567576924019015"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113379","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The outcomes of primary membranous nephropathy treated with cyclophosphamide are superior to calcineurin inhibitors in patients with renal vascular lesions: A multi-center retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113379","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113379"}}